Skip to main content
Year archive

Elanix Biotechnologies AG — 2018 filings

All 24 regulatory filings released by Elanix Biotechnologies AG (ELN) in 2018, sourced directly from the official regulator.

24 Filings
2018 Period
2018 filings (24)
Filing Released Lang
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-12-19 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-12-19 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-12-12 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-11-30 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements
2018-11-29 English
Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG
Director's Dealing
2018-11-23 English
Elanix Biotechnologies AG: Frau Prof. Lee Ann Laurent-Applegate wird neuer Vorstand
Board/Management Information
2018-11-12 German
Elanix Biotechnologies AG: Widerruf der Bestellung von Herrn Tomas J. Svoboda (CEO) als Vorstandsmitglied
Board/Management Information
2018-11-12 German
Elanix Biotechnologies AG: Elanix Biotechnologies AG has placed 301,763 shares of the current cash capital increase and is negotiating further financing opportunities
Share Issue/Capital Change
2018-10-01 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-09-28 English
Elanix Biotechnologies AG getting confirmation of Outperform Recommendation by goetzpartners securities
Regulatory Filings
2018-08-09 English
Elanix Biotechnologies AG announces cash capital increase with indirect subscription rights from currently EUR 7,779,139 by up to EUR 777,910 to up to EUR 8,557,049
Share Issue/Capital Change
2018-07-24 English
Elanix Biotechnologies AG beschliet unter Ausnutzung des Genehmigten Kapitals eine Barkapitalerhohung mit mittelbarem Bezugsrecht im Umfang von bis zu 10% entsprechend rund 2,1 Mio. EUR
Capital/Financing Update
2018-07-24 German
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-07-03 English
Elanix Biotechnologies AG: Elanix Biotechnologies AG has placed all 679,920 shares of the current cash capital increase
Share Issue/Capital Change
2018-06-11 English
Elanix Biotechnologies AG: Elanix Biotechnologies AG Strengthens Executive Team with Appointment of Egon Minar as Chief Operating Officer / Chief Financial Officer
Board/Management Information
2018-05-29 English
Elanix Biotechnologies AG resolves a capital increase of up to 10 percent with the exclusion of subscription rights using the authorized capital
Capital/Financing Update
2018-05-28 English
Elanix Biotechnologies AG: Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R)
M&A Activity
2018-05-23 English
Elanix Biotechnologies Raises up to 2.5 Million EUR Through Standby Equity Distribution Agreement and Announces Preliminary Fiscal Year 2017 Results
Share Issue/Capital Change
2018-04-30 English
Elanix Biotechnologies AG secures up to EUR 2.5 Million SEDA (Standby Equity Distribution Agreement) financing
Capital/Financing Update
2018-04-30 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2018-02-20 English
Elanix Biotechnologies AG Raises EUR 1.125 Million gross proceeds from Completed Capital Increase and Signs Term-Sheet for Financing Facility of up to EUR 11 Million
Share Issue/Capital Change
2018-02-14 English
Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of 300,019 shares from the current cash capital increase and signs a Term Sheet for financing facility of up to EUR 11 Million
Share Issue/Capital Change
2018-02-14 English
Elanix Biotechnologies AG Appoints Baader Bank as a New Designated Sponsor and goetzpartners securities for Corporate Broking
Board/Management Information
2018-01-23 English